CARSON CITY, Nev. - BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company, has announced the pricing of its registered direct offering. The company is offering 1,146,000 shares of common stock at a price of $2.83 per share. This transaction is expected to result in gross proceeds of approximately $3.2 million. The proceeds are intended for working capital and general corporate purposes.
The offering is being conducted at-the-market under Nasdaq rules, with ThinkEquity acting as the sole placement agent. The offering, along with a concurrent private placement, is anticipated to close on October 29, 2024, subject to customary closing conditions.
BioVie's securities are being offered pursuant to a shelf registration statement, including a base prospectus, filed with the U.S. Securities and Exchange Commission (SEC) on August 18, 2023, and declared effective as of August 28, 2023. A final prospectus supplement and accompanying prospectus detailing the offering terms will be filed with the SEC.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities, and there will be no sale of these securities in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
BioVie is focused on developing drug therapies for chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders such as Long COVID, Alzheimer's disease, and Parkinson’s disease. Its drug candidate, bezisterim, targets neuroinflammation and insulin resistance, factors implicated in Alzheimer's and Parkinson’s diseases. Additionally, the company's orphan drug candidate BIV201 is under evaluation for Phase 3 clinical testing for liver cirrhosis and ascites, with guidance from the FDA.
The information presented in this article is based on a press release statement from BioVie Inc.
In other recent news, BioVie Inc. has been active in raising funds through stock offerings and securing patents for novel drug formulations. The company has announced two significant stock offerings, one aiming to generate about $6 million and the other targeting approximately $6.7 million in proceeds. Both offerings include the issuance of common stock and warrants, with ThinkEquity serving as the sole placement agent.
BioVie has also been successful in securing patents for a novel liquid formulation of terlipressin in multiple countries, including Japan, the United States, India, and Chile. This formulation aims to improve the management of ascites in patients with liver cirrhosis, particularly in home care settings.
The company has also received approval to proceed with a Phase 2 clinical trial of bezisterim, an investigational drug for the treatment of neurological symptoms associated with long COVID. This approval opens up the possibility of an additional $12.6 million in grant funding from the U.S. Department of Defense.
In corporate news, BioVie reported the resignation of director Steve Gorlin and has regained compliance with Nasdaq's minimum bid price requirement, following a 1-for-10 reverse stock split of its Class A common stock. These recent developments highlight BioVie's ongoing commitment to pharmaceutical innovation and corporate evolution.
InvestingPro Insights
BioVie Inc.'s recent pricing of its registered direct offering comes at a time when the company's financial metrics and market performance present a mixed picture. According to InvestingPro data, BioVie's market capitalization stands at $21.89 million, reflecting its status as a small-cap biopharmaceutical company.
The company's stock has shown significant volatility, with InvestingPro Tips highlighting that it "generally trades with high price volatility." This is evident in the stark contrast between its short-term and long-term performance. While BioVie has seen a strong 138.33% return over the last month, it has experienced a substantial 91.03% decline over the past year.
BioVie's financial health presents some positive aspects amidst challenges. An InvestingPro Tip notes that the company "holds more cash than debt on its balance sheet," which could provide some financial flexibility as it pursues its clinical-stage drug development programs. Additionally, "liquid assets exceed short term obligations," potentially offering a buffer against immediate financial pressures.
However, investors should be aware that BioVie is "not profitable over the last twelve months," with an adjusted operating income of -$32.18 million. The company's focus on developing therapies for chronic conditions like Alzheimer's and Parkinson's diseases requires significant R&D investment, which is reflected in its current financial performance.
For those interested in a deeper analysis, InvestingPro offers 11 additional tips for BioVie, providing a more comprehensive view of the company's financial situation and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.